Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X
Animals
Benzothiazoles
/ pharmacology
Caspases
/ metabolism
Cell Line, Tumor
Cell Survival
/ drug effects
Chick Embryo
Child
Drug Synergism
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Isoquinolines
/ pharmacology
Membrane Potential, Mitochondrial
/ drug effects
Mice
Myeloid Cell Leukemia Sequence 1 Protein
/ metabolism
Neuroblastoma
/ drug therapy
Osteosarcoma
/ drug therapy
Pyrimidines
/ pharmacology
Rhabdomyosarcoma
/ drug therapy
Sarcoma, Ewing
/ drug therapy
Thiophenes
/ pharmacology
bcl-X Protein
/ metabolism
A-1331852
Apoptosis
BCL-2 proteins
Rhabdomyosarcoma
S63845
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
10 07 2020
10 07 2020
Historique:
received:
16
12
2019
revised:
28
02
2020
accepted:
28
02
2020
pubmed:
8
3
2020
medline:
6
1
2021
entrez:
8
3
2020
Statut:
ppublish
Résumé
With the development of potent and selective inhibitors of MCL-1 (S63845) and BCL-X
Identifiants
pubmed: 32145345
pii: S0304-3835(20)30110-5
doi: 10.1016/j.canlet.2020.02.041
pii:
doi:
Substances chimiques
A-1331852
0
BCL2L1 protein, human
0
Benzothiazoles
0
Isoquinolines
0
MCL1 protein, human
0
Myeloid Cell Leukemia Sequence 1 Protein
0
Pyrimidines
0
S63845
0
Thiophenes
0
bcl-X Protein
0
Caspases
EC 3.4.22.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19-32Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None to declare.